The use of Nystatin for preparing a orally, intranasally or topically applicable pharmaceutical composition useful for the stimulation of bodycells of a human patient in the treatment or prevention or a variety of diseases, e.g.: a) viral or bacterial infections, b) diseases associated with an impaired function of MHC class I and II and/or other integral proteins, c) cholesterol associated diseases, d) cancer, e) ulcers, f) degenerative diseases, or useful in wound-healing.
1. The use of Nystatin or a functional derivative thereof for preparing an orally, intranasally or topically administrable pharmaceutical composition useful for the stimulation of bodycells of a human patient.
2. The use of claim 1 wherein modulation of the plasma electrochemical potential (EP) induces the bodycell stimulation.
3. The use of claim 2, wherein modulation is caused by the depolarization of the cells.
4. The use of claim 3, wherein energy transduction across the plasma membrane is elicited in the process of cell depolarization.
5. The use of one of the claims 1 to 5, for preparing a pharmaceutical composition useful for treatment of a patient suffering from at least one of the following diseases:
b) diseases associated with an impaired function of MMC class I and II and/or other integral proteins,
c) cholesterol associated diseases,
f) degenerative diseases,
or useful in wound-healing.
6. The use of claim 5, wherein the viral infection is caused by an infection with a virus selected from picornaviridae, caliciviridae, togaviridae, flaviviridae, coronaviridae, rhabdoviridae, filoviridae, paramyxoviridae, orthomyxoviridae, bunyaviridae, arenaviridae, reoviridae, retroviridae, hepadnaviridae, parvoviridae, papovaviridae, adenoviridae, herpesviridae, poxviridae, Epstein-Barr virus, and cytomegalovirus.
7. The use of claim 6, wherein the virus is selected from HIV HIV-2, HTLV-I, HTLV-II, Hepatitis-A-Virus, Hepatitis-B-Virus, Herpes-Simplex Virus, Herpes-Zoster Virus, Vesicular-Stomatitis-Virus, Influenza Virus, Reuscher-Leukemia Virus, Sindbis-Virus, Vaccinia Virus, or a virus triggering Recurrent Aphthous Stomatitis.
8. The use of claim 5, wherein the bacterial infection is caused by a gram-negative, gram-positive, aerobic or anaerobic bacterium.
9. The use of claim 5, wherein the disease is associated with an impaired function of MHC class I and II and/or other integral proteins and is selected from diseases of the bone tissue, gastrointestinal diseases, hematologic diseases, skin diseases, endocrine and genetic disorders, neurologic disorders, renal disorders, infections, and genetic disorders of lymphokines, complement, other humoral factors and receptors.
10. The use of claim 9, wherein the disorder is selected from rheumatoid arthritis, food-sensitive enteropathy, neurodermatitis, chronic fatigue syndrom, multiple sclerosis, and Alzheimer disease.
11. The use of claim 5, wherein the cholesterol associated disease is selected from, atherosclerosis, Alzheimer disease, prostatic hyperplasia, postmenopausal syndrome, gallstones, infertility, and acne.
12. The use of claim 5, wherein the patient suffers from a solid cancer or leukaemia.
13. The use of claim 12 in combination with at least one additional cytostatic agent.
14. The use of claim 5, wherein the patient suffers from, gastric ulcer, duodenal ulcer, ulcers of the mucosa of the intestinal tract, inflammations of the mucosa of the gastrointestinal tract, decubitus, ulcus cruri.
15. The use of claim 5, where the patient suffers from lesions of the skin, burns and wounds.
16. The use of claim 5, wherein the patient suffers from osteoporosis.
17. The use of claim 5 for the prevention of postoperative infections, or for treating sepsis.
18. The use of claim 5, for enhancing the allo-tolerance of a patient to a future organ transplantate.